Center for Urogynecology and Reconstructive Pelvic Surgery | NYU Langone Health
Specialists at NYU Langone’s Center for Urogynecology and Reconstructive Pelvic Surgery offer treatment for a range of urologic and gynecologic conditions.
Center for Urogynecology and Reconstructive Pelvic Surgery Doctors | NYU Langone Health
Find a doctor at the Center for Urogynecology and Reconstructive Pelvic Surgery at NYU Langone.
Center for Vulvar Health | NYU Langone Health
NYU Langone’s Center for Vulvar Health offers expert care for chronic vulvar pain, irritation, and skin conditions like lichen sclerosus and lichen planus.
Center for Vulvar Health Doctors | NYU Langone Health
Find a doctor at the Center for Vulvar Health at NYU Langone.
Center for Women’s Sports Medicine | NYU Langone Health
Experts at NYU Langone’s Center for Women’s Sports Medicine provide complete orthopedic and rehabilitation care to female athletes of all ages.
Center for Women’s Sports Medicine Doctors | NYU Langone Health
Find a doctor at the Center for Women’s Sports Medicine at NYU Langone.
Center for Young Athletes | NYU Langone Health
Doctors at the Center for Young Athletes, part of Hassenfeld Children’s Hospital at NYU Langone, care for young people with sports injuries.
Centers & Programs | NYU Langone Health
Perlmutter Cancer Center offers specialized services through our centers and programs across Manhattan, Brooklyn, Queens, and Long Island.
Cerebral Palsy in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone provide comprehensive care for babies, children, and teens with cerebral palsy.
Cerliponase alfa Observational Study
This is a, multicenter, observational study for patients with a confirmed diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as TPP1 deficiency, who intend to be or are currently being treated with cerliponase alfa.The primary objective of the study is to evaluate the long-term safety of cerliponase alfa in patients with neuronal ceroid lipofuscinosis Type 2 (CLN2 disease). The secondary objectives of this study are to further assess the occurrence of serious hypersensitivity reactions (including anaphylaxis), serious cardiovascular adverse events, serious devicerelated complications, and to evaluate the effects of Grade III or higher serious adverse events (SAEs) on patient performance on the CLN2 clinical rating scale (motor and language domains).